EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sutro Biopharma's enterprise value is $-163.11 Mil.
Sutro Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-199.21 Mil. Therefore, Sutro Biopharma's EV-to-EBITDA for today is 0.82.
The historical rank and industry rank for Sutro Biopharma's EV-to-EBITDA or its related term are showing as below:
STRO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.27 Med: -1.21 Max: 25.37
Current: 0.82
During the past 9 years, the highest EV-to-EBITDA of Sutro Biopharma was 25.37. The lowest was -32.27. And the median was -1.21.
STRO's EV-to-EBITDA is ranked better than 72.03% of 472
companies
in the Biotechnology industry
Industry Median: 9.81
vs STRO: 0.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sutro Biopharma EV-to-EBITDA Historical Data
The historical data trend for Sutro Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sutro Biopharma's EV-to-EBITDA
For the Biotechnology subindustry, Sutro Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's EV-to-EBITDA falls into.
Sutro Biopharma's current Enterprise Value is $-163.11 Mil.
Sutro Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-199.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sutro Biopharma's PE Ratio (TTM) for today is calculated as:
Sutro Biopharma's share price for today is $0.7632.
Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.980.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Sutro Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STRO has been successfully added to your 